Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medherant Limited
During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.
Hugel says its longer-term global growth strategy will remain intact after a major acquisition of the Korean medical aesthetics company by a consortium including GS Group.
The USITC has issued a final determination in the long-running botulinum toxin dispute between Daewoong and Medytox, sharply cutting the length of Daewoong’s product import ban and reversing its initial decision with respect to Medytox’s bacterial strain. But the dispute seems poised to continue as Daewoong vows further legal steps.
USITC’s initial decision in the Medytox and Daewoong botulinum dispute is favorable to Medytox and poised to take a toll on the Korean firm and partner Evolus as they face a 10-year ban on imports of their product to the US.
- Medical Devices
- Drug Delivery